Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

NCT00261365 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Stage III or IV Malignant Melanoma

Interventions

DRUG: Ipilimumab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb